RUNX2 and neoplasm: In addition to osteogenesis-related genes, RUNX2 has an ability to transactivate its downstream target genes involved in tumor progression, invasion and metastasis such as MMP9, MMP13, VEGF, survivin, IL-8 and TGFβR [14–16, 122–124].